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• Palmitic  acid  (PA)  increases  microglial  orexin  receptor  1  expression.
• PA  increases  microglial  pro-inﬂammatory  cytokine  release.
• Orexin  A  reduces  microglial  pro-inﬂammatory  cytokine  release.
• Orexin  A  attenuates  hypothalamic  cell  death  induced  by  PA-activated  microglia.
• Orexin  A  may  function  as  an  immunomodulatory  regulator  of microglia.
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a  b  s  t  r  a  c  t
Excess  dietary  saturated  fatty  acids  such  as palmitic  acid  (PA)  induce  peripheral  and  hypothalamic  inﬂam-
mation.  Hypothalamic  inﬂammation,  mediated  in  part  by  microglial  activation,  contributes  to  metabolic
dysregulation.  In rodents,  high  fat diet-induced  microglial  activation  results  in  nuclear  translocation  of
nuclear  factor-kappa  B (NFB),  and  increased  central  pro-inﬂammatory  cytokines  tumor  necrosis  factor
alpha  (TNF-)  and  interleukin-6  (IL-6).  The  hypothalamic  neuropeptide  orexin  A (OXA,  hypocretin  1) is
neuroprotective  in  brain.  In  cortex,  OXA  can  also  reduce  inﬂammation  and  neurodegeneration  through
a microglial-mediated  pathway.  Whether  hypothalamic  orexin  neuroprotection  mechanisms  depend
upon microglia  is  unknown.  To  address  this  issue,  we evaluated  effects  of  OXA and  PA on inﬂamma-
tory  response  in  immortalized  murine  microglial  and hypothalamic  neuronal  cell  lines.  We  demonstrate
for  the  ﬁrst  time  in microglial  cells  that  exposure  to PA increases  gene  expression  of orexin-1  receptor
but  not  orexin-2  receptor.  Pro-inﬂammatory  markers  IL-6,  TNF-,  and  inducible  nitric  oxide  synthase  in
microglial  cells  are  increased  following  PA  exposure,  but  are  reduced  by  pretreatment  with  OXA.  The  anti-
inﬂammatory  marker  arginase-1  is  increased  by  OXA.  Finally,  we  show  hypothalamic  neurons  exposed
to conditioned  media  from  PA-challenged  microglia  have  increased  cell  survival  only  when  microglia
were  pretreated  with  OXA.  These  data  support  the  concept  that  OXA  may  act as  an  immunomodulatory
regulator of  microglia,  reducing  pro-inﬂammatory  cytokines  and  increasing  anti-inﬂammatory  factors
to promote  a favorable  neuronal  microenvironment.
Published  by  Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under  the  CC BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nuclear factor-kappa B; OXA, orexin A/hypocretin 1; OX1R, orexin receptor 1; OX2R,
orexin receptor 2; IL-6, interleukin 6; LPS, lipopolysaccharide; TLR-4, toll like recep-
tor  4; RT-PCR, real time polymerase chain reaction; RFU, relative ﬂuorescence units;
ELISA, enzyme-linked immunosorbent assay; BSA, bovine serum albumin.
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1. Introduction
The orexins (orexins A and B; hypocretin 1 and 2) are hypotha-
lamic peptides produced in lateral hypothalamic neurons and
released widely throughout the CNS [1,2]. Orexin A (OXA) and B
(OXB) regulate homeostatic mechanisms of energy balance and
metabolism [3] through activation of two G-protein coupled recep-
tors, orexin receptors 1 and 2 (OX1R and OX2R, respectively) [2].
Recent studies have shown that orexin plays a role in neuropro-
http://dx.doi.org/10.1016/j.neulet.2015.08.033
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tection [3,4], in part by reducing lipid peroxidation, apoptosis,
and inﬂammation [5–8]. Data suggest that the neuroprotective
effects of orexin could rely on modulation of microglia, the resident
immune cells of the brain.
Microglia are initiators of the neuroinﬂammatory response and
are highly reactive to endogenous signaling. Microglia are highly
dynamic, transitioning between neurotoxic pro-inﬂammatory
(M1) and neuroprotective (M2) phenotypes. For example, following
cerebral ischemic events, microglia are ﬁrst activated to a neu-
roprotective M2  phenotype as oxygen levels decrease, and then
switch to a pro-inﬂammatory M1  phenotype, inducing cell death
[9]. While inﬂammation is a component of a normal immune
response, chronic activation to M1  pro-inﬂammatory phenotypes
can cause microglia to become refractory and contribute to subse-
quent neuronal dysfunction [10].
Several lines of evidence suggest a role for orexin in mod-
ulation of microglia. In cerebral ischemia models, pretreatment
with OXA reduces infarct size through a microglial-mediated path-
way [8]. Microglia may  also become more sensitive to orexin
signaling after activation. The potent pro-inﬂammatory agonist
lipopolysaccharide (LPS) increases tumor necrosis factor alpha
(TNF-) in microglia, but also increases OX1R expression, and OXA
treatment prior to LPS exposure reduces TNF- in microglia [8].
These data indicate that increased microglial OX1R could enhance
responsiveness to orexin, thus enhancing capability to counter an
inﬂammatory insult. We  are especially interested in how these
orexin–microglia dynamics might impact brain health in the con-
text of diet-induced obesity.
Dietary intake inﬂuences neuronal function, overall brain
health, and cognition [11]. High fat diet increases circulating pro-
inﬂammatory cytokines released from microglial cells, resulting in
hypothalamic neuroinﬂammation and neurodegeneration [12,13].
Chronic intake of saturated fatty acids (SFA) such as palmitic
acid (PA, C16:0), activate microglia to an M1  phenotype, elicit-
ing the release of pro-inﬂammatory cytokines [14,15]. High fat
diets cause this response by activating nuclear translocation of
microglial nuclear factor-kappa B (NFB), initiating release of pro-
inﬂammatory cytokines such as TNF- and interleukin-6 (IL-6)
[13–15]. Palmitic acid activates microglia through a toll like recep-
tor 4 (TLR-4)-dependent pathway, inducing the release of TNF-
and IL-6 [14]. Further, microglia activated by SFA via TLR-4 induce
neuronal cell death [14]. Given the above ﬁndings on orexin action
in microglia, orexin signaling might promote microglia switch-
ing to a protective M2  phenotype, protecting against palmitic acid
induced inﬂammation.
The objective of these studies was to determine if orexin reduces
PA-induced neuroinﬂammation by altering microglial M1/M2  phe-
notype dynamics. To test whether orexin treatment inﬂuences
microglial phenotype, we evaluated the effect of OXA on PA-
induced release of pro-inﬂammatory cytokines in an immortalized
murine microglial cell line (designated BV2). We ﬁrst validated that
PA activates microglia to an M1 state via TLR-4. In our next set
of experiments, we tested whether OXA pretreatment inﬂuenced
levels of the M1  pro-inﬂammatory markers IL-6, TNF-; inducible
nitric oxide synthase (iNOS); and the M2 anti-inﬂammatory marker
arginase-1 in microglia. Finally, we performed a series of studies to
determine how conditioned media from these prior tests altered
hypothalamic neuronal survival.
2. Materials and methods
2.1. Cell culture and reagents
Immortalized murine microglial cells (BV2) and adult murine
hypothalamic cells (mHypoA-1/2, cited elsewhere as CLU172; CEL-
Lutions Biosystems) [16–18] were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) plus 10% fetal bovine serum and 1% peni-
cillin, streptomycin, and neomycin (Invitrogen) and maintained at
37 ◦C with 5% CO2. Orexin A peptide (American Peptides) was  sus-
pended in phosphate buffered saline (PBS, Invitrogen) and diluted
to 300 nM in DMEM.  Palmitic acid (Sigma–Aldrich) was conjugated
to fatty acid free bovine serum albumin (BSA) [19] and diluted to
0.1 mM in DMEM.  Lipopolysaccharide (Sigma–Aldrich) was  recon-
stituted in PBS and diluted to 0.4 g (100 ng/ml) in DMEM. The
TLR-4 inhibitor TAK-242 (EMD Millipore) was reconstituted in
DMSO and diluted to 100 nM in DMEM.
For microglial experiments with OXA, BV2 cells were seeded in
T-25 ﬂasks at 7 × 105 cells and grown to ∼80% conﬂuency. Con-
centrations of OXA and PA are based on Xiong et al. and Wang
et al. [8,14]. For all assays, cells were serum starved for 24 h. The
experiment was completed in two  stages: a 1 h pre-incubation
followed by a 4 h challenge. Pre-incubation used either vehicle
(PBS) or OXA (300 nM). For challenge, cells were exposed to vehi-
cle (fatty acid free BSA), PA (0.1 mM),  or LPS (0.4 g; 100 ng/ml).
There were a total of 5 treatment groups: vehicle–vehicle (control),
vehicle-LPS, vehicle-PA, OXA-vehicle, and OXA-PA. After treatment,
supernatant and cells were rapidly collected and stored at −20 ◦C.
Supernatant from microglial cultures treated as described here
was used as conditioned media for hypothalamic neuronal cultures
(described below).
For microglial experiments with TAK-242, cells were seeded in
6 well plates at 3.5 × 105 cells per well and grown to ∼80% con-
ﬂuency. Concentrations and time points were based on Matsunaga
et al. and Takashima et al. [20,21]. Cells were serum starved for 24 h.
TAK-242 (100 nM)  or vehicle was added 20 min  prior to incubation
with PA (0.1 mM)  or vehicle for 4 h.
2.2. Real-time RT-PCR
Total RNA was extracted from BV2 cells with Trizol (Invitrogen)
as previously described [5,22]. Concentrations were determined
using spectrophotometric readings at 260 and 280 nm (Nanodrop
8000, Thermo Fisher Scientiﬁc) and 2.5 g RNA was used for each
reaction. Primer sequences were generated using MacVector 15 for
OX1R (NM 198959), OX2R (NM 198962), IL-6 (NM 031168), iNOS
(NM 010927), arginase-1 (NM 007482) and GAPDH (NM 017008).
Relative mRNA expression of target genes was  determined using
SYBR Green detection normalized to GAPDH using the -CT
method [23].
2.3. Enzyme-linked immunosorbent assay (ELISA)
TNF- level in culture media was  determined using an ELISA
kit (BioLegend Inc.). Concentrations were determined using a
spectrophotometer (SpectraMax-M5; Molecular Probes). Data are
presented as picograms of TNF-/ml.
2.4. Cell viability assay for hypothalamic cells
mHypoA-1/2 cells were seeded in a 96 well plate at 5 × 103 cells
per well overnight. Amicon Filters (Millipore) were used to remove
PA and OXA and concentrate conditioned media (supernatant from
microglial cultures described above) [24]. Concentrated condi-
tioned media was  used at a six-fold concentration and added to
mHypoA-1/2 cells for 24 h. Time points were based on previously
described studies [14,25,26]. Cell survival was determined using a
resazurin-based assay (Presto Blue, Invitrogen) producing a ﬂuores-
cent signal [5]. Activity was  determined using a spectrophotometer
(SpectraMax-M5) and presented as percent relative ﬂuorescence
units (RFU) change vs. control.
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2.5. Statistical methods
Signiﬁcance differences were determined by unpaired, two-
tailed t-tests using Graph Pad Prism 5.
3. Results
3.1. Palmitic acid activates BV2 microglia via TLR-4
To verify that PA induces pro-inﬂammatory cytokine release
from microglial cells through activation of TLR-4 receptor, BV2
microglial cells were treated with the TLR-4 inhibitor TAK-242 (or
vehicle control; C) in the presence or absence of PA for 4 h. As
expected, PA increased TNF- secretion by 90 percent compared
to control, by 320 percent vs. TAK-242 only, and by 400 percent vs.
TAK-242 plus PA (p < 0.001 vs. C, p < 0.0001 vs TAK-242 and TAK-242
plus PA). Treatment with TAK-242 signiﬁcantly reduced endoge-
nous TNF- production. Further, TAK-242 attenuated PA induced
TNF- secretion. (Fig. 1A)
3.2. Palmitic acid increases expression of microglial orexin 1
receptor
To determine if PA increases microglial OX1R expression in our
model, we pretreated BV2 microglia for 1 h with either OXA or
vehicle control. Following pretreatment, microglia were exposed
to PA, LPS, or vehicle for 4 h. Palmitic acid and LPS increased expres-
sion of OX1R (Fig. 1B; p <0.05 vs. control and OXA only) by 55 and
75 percent respectively, but not OX2R (Fig. 1C) in microglial cells
following 4 h exposure.
3.3. Orexin A suppresses pro-inﬂammatory markers and
increases expression of anti-inﬂammatory M2  marker
arginase-1arginase-1 in microglial cells
Gene expression of the pro-inﬂammatory cytokine IL-6 is
increased by 3.5 fold following PA and LPS exposure (Fig. 1D;
p < 0.0001 vs. control, p < 0.001 vs. OXA only). Further, OXA pretreat-
ment prior to PA challenge reduced IL-6 expression by 50 percent
compared to PA only (Fig. 1D; p < 0.0001 vs. control, p < 0.001 vs.
OXA only). Expression of pro-inﬂammatory marker iNOS is also
increased following PA and LPS exposure by 60 and 75 percent
respectively (Fig. 1E; p < 0.001 vs control, p < 0.05 vs OXA and
OXA/PA). Conversely, OXA pretreatment attenuated PA–induced
increase of iNOS expression (Fig. 1E). To test whether OXA inﬂu-
ences TNF- secretion in microglia, BV2 cells were pretreated
with OXA or vehicle and challenged with PA, LPS, or vehicle as
described above. An ELISA for TNF- in the supernatant showed
that PA and LPS treatment increased TNF- secretion by 90 percent
compared to vehicle control (p < 0.0001) or OXA treatment only
(p < 0.0001) (Fig. 1F). Microglia treated with OXA plus PA reduced
TNF- secretion by 20 percent compared to PA only, but not to vehi-
cle control (Fig. 1F; p < 0.0001 vs. control and OXA only). As shown in
Fig. 1G, OXA increased arginase-1 gene expression by 250 percent
(p < 0.001 vs. control, p < 0.05 vs. PA and LPS). Notably, OXA pretreat-
ment prior to PA challenge also increased arginase-1 expression by
100 percent (p < 0.001 vs. control, PA, and LPS).
3.4. Orexin A attenuates hypothalamic neuronal cell death in
microglial-conditioned media
Exposure to conditioned media from PA–treated microglia
induces neuronal cell death due to the release of pro-inﬂammatory
cytokines and other inﬂammatory factors [14]. We  tested whether
OXA treatment could affect inﬂammatory properties of conditioned
media from PA-challenged microglia. Hypothalamic cells exposed
to conditioned media from microglia treated with OXA  only or
pretreated with OXA and challenged with PA showed increased
viability compared to hypothalamic cells exposed to conditioned
media from PA-activated microglia (Fig. 1H; p < 0.0006 vs. OXA,
p < 0.05 vs. OXA/PA). Further, cells exposed to conditioned media
from PA–activated microglia had increased cell death compared to
vehicle control (Fig. 1H; p = 0.0005).
4. Discussion
Microglia are vital to neuronal health by maintaining a favor-
able microenvironment within the CNS [27,28]. Communication
between neurons, microglia, and other CNS cells is highly dynamic
and responsive to environmental stimuli. This balance can be
disturbed if microglial activation state tips toward a chronic
inﬂammatory phenotype, as is observed in obesity [15,29,30]. An
important unanswered question is whether it is the high fat diet
or obesity itself that directly induces microglial activation. High fat
diets and obesity, either independently or synergistically, have the
same consequences: microglial activation and prolonged circula-
tion of pro-inﬂammatory cytokines [15,29,30]. Our data conﬁrm
prior reports indicating PA induces microglial cytokine produc-
tion through a TLR-4 dependent pathway (Fig. 1A) [14]. We  have
shown that OX1R expression is increased in microglia challenged
with PA or LPS (Fig. 1B). To the best of our knowledge, this is the
ﬁrst report demonstrating that PA increases OX1R expression in
microglia. Our data also suggest that orexin can alter the activation
state of microglia, reducing microglial M1  pro-inﬂammatory state
by promoting the conversion to M2  phenotype, as OXA pretreat-
ment reduced microglial M1  pro-inﬂammatory response during PA
challenge (Fig. 1D–F). Consistent with previous reports [8], these
data support that OXA can act as an immunomodulatory regu-
lator of microglia. Most importantly, we show for the ﬁrst time
both that hypothalamic cells exposed to conditioned media from
OXA and OXA/PA treated microglia have increased cell survival
compared to those exposed to media from PA-activated microglia
without orexin, and that OXA pretreatment may  shift microglia to
an M2 protective phenotype (Fig. 1G–H). Our results demonstrate
OXA modulates microglial activation states in response to PA expo-
sure by reducing pro-inﬂammatory cytokine release and increasing
anti-inﬂammatory markers.
In microglia activated by PA, addition of OXA signiﬁcantly
reduced iNOS expression. Nobunaga et al. demonstrated that
microglial derived iNOS contributed to a loss of orexin producing
neurons and subsequent metabolic dysfunction in mice fed a high
fat diet [31]. Reduction of iNOS expression due to OXA  modula-
tion in our study could therefore help in maintaining a favorable
environment for surrounding cells. Likewise, conditioned media
from PA-activated microglia did not induce hypothalamic cell death
when microglia were pretreated with OXA prior to PA challenge. It
is plausible that increasing the pretreatment time with OXA prior
to PA exposure could further reduce pro-inﬂammatory cytokine
release.
Our ﬁndings that PA increases OX1R expression in microglial
cells are consistent with previous ﬁndings indicating that the
pro-inﬂammatory stimuli LPS also increases OX1R expression [8].
Increased microglial OX1R expression in response to a TLR-4 medi-
ated pro-inﬂammatory stimulus could represent a compensatory
response to reduce the release of inﬂammatory cytokines. Oth-
ers have demonstrated that astrocytes, a subset of glial support
cells, are responsive to OXA through OX1R by increasing migra-
tion following OXA exposure, further indicating OXA is modulatory
not only through neuronal cells but also glial cells [32]. Until
recently, microglia were thought to be passive support cells, but are
now understood to contribute to ﬁne-tuning neural-glial circuitry
C.M. Duffy et al. / Neuroscience Letters 606 (2015) 140–144 143
Fig. 1. (A) Palmitic acid activates microglia via TLR-4. TNF- secretion from microglial BV2 cells increases following 4 h PA exposure. Inhibiting TLR-4 attenuates PA–induced
TNF-  secretion. Microglia treated with TLR-4 inhibitor (TAK-242) have signiﬁcantly reduced TNF- secretion (p < 0.001 PA vs. vehicle control (C), p < 0.0001 PA vs. TAK-
242,  and TAK-242 + PA, p < 0.001C vs. TAK-242 and TAK-242+PA). (B,C) Palmitic acid increases orexin 1 receptor expression. Microglia exposed to PA or LPS show increased
OX1R  expression (B) but not OX2R expression (C). Pretreatment of microglia with OXA before PA challenge increased OX1R expression and reduced OX2R expression.
Different  letters above bars represent statistical signiﬁcance at p < 0.05 OXA vs. OXA/PA. (D) Orexin A suppresses pro-inﬂammatory IL-6 expression in microglial cells. Pro-
inﬂammatory marker IL-6 expression is increased in BV2 microglia following PA and LPS exposure. Pretreatment of microglia with OXA before PA challenge reduces IL-6
expression compared to microglia exposed to PA only, but remains increased relative to vehicle (p < 0.05 C vs. OXA, p< 0.001 LPS vs. OXA and OXA/PA, p < 0.001 PA vs. OXA and
OXA/PA p < 0.0001 C vs. LPS, PA, and OXA/PA). (E) Orexin A suppresses pro-inﬂammatory iNOS expression. Palmitic acid and LPS increase microglial iNOS expression, while
OXA  pretreatment attenuates PA-induced iNOS expression (PA and LPS p < 0.001 vs control, p < 0.05 vs OXA and OXA/PA). (F) Orexin A reduces TNF- secretion from BV2
microglial cells. PA and LPS treatment increase TNF- secretion compared to vehicle- or OXA only- treated microglia. Pretreatment of microglia with OXA before PA challenge
reduces TNF- secretion compared to PA only- but not vehicle- treated microglia. Different letters above bars represent statistical signiﬁcance at p < 0.0001. (G) Orexin A
increases M2  marker arginase-1 gene expression. Pretreatment with OXA prior to PA challenge increases arginase-1 gene expression (OXA/PA p < 0.001 vs. control, p < 0.05
vs.  PA and LPS). OXA alone increases arginase-1 expression in microglial cells (p < 0.001 OXA vs. control, PA, and LPS). (H) Orexin A attenuates hypothalamic neuronal cell
death  in microglial-conditioned media. Adult hypothalamic cells have increased cell death following 24 h exposure to conditioned media from microglia stimulated with PA.
Hypothalamic cells exposed to conditioned media from microglia pretreated with OXA before PA challenge, or vehicle-treated microglia, have reduced cell death compared
to  those exposed to media from PA-challenged microglia. p < 0.0001 Vehicle vs. PA, p < 0.001 PA vs. OXA/PA, p < 0.0001 PA vs. OXA (I) Hypothesized Orexin A microglial
immunomodulation pathway. We hypothesize that OXA reduces M1  microglial activation and increase M2 microglial activation to maintain neuronal survival. Saturated
fatty  acid challenge (PA) induces an M1  microglial phenotype and the release of pro-inﬂammatory cytokines, contributing to neurodegeneration. Orexin A may  inﬂuence
proportion of M1 microglia by reducing rate of activation or potentially by aiding in conversion between M1 and M2  states.
through cultivating synapses and altering plasticity in healthy and
diseased brains [33,34]. Additionally, microglia maintain the brain
microenvironment through phagocytizing debris, pathogens, dead
cells, and misfolded proteins. In neurological disorders, microglia
can be chronically activated to M1  phenotypes, resulting in an
unfavorable environment for neuronal networks [35,36]. Here we
lay the groundwork for understanding how OXA can modulate
microglia responses to promote neuronal survival. Performing
a more complete proﬁle of other pro- and anti-inﬂammatory
cytokines in future studies could provide insight into how priming
microglia with OXA can provide a favorable brain microenviron-
ment and maintain neuronal health. While we do not yet fully
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know how OXA modulates microglia, one mechanism may  be
through shifting microglia toward an M2  phenotype, or at least
slowing rate of conversion to an M1  state. In other studies of acute
neuroinﬂammatory responses, microglia activated to an M2  protec-
tive phenotype, including increased arginase-1 expression, showed
reduction in neuronal injury and inﬂammation [37–40]. Promotion
of M2  microglial function has been demonstrated to either support
or enhance neural-glial cross talk via increases in the microglial
CX3CR1 (fractalkine) receptor [41]. Fractalkine receptor increase
has not been evaluated with respect to OXA stimulation, but merits
further research.
In summary, these data support the hypothesis that orexin inﬂu-
ences the M1/M2  activation state of microglia during challenge
with SFA, reducing pro-inﬂammatory cytokine release to maintain
neuronal survival in the surrounding microenvironment (Fig. 1).
Future work will examine the implications of orexin on microglial
dynamics in the context of diet and obesity. In other inﬂammatory
diseases, microglia have been proﬁled to gain a better understand-
ing of disease status [42]. Chronic microglial activation in response
to high fat diet and overnutrition has yet to be fully character-
ized. Delineating microglial phenotypes in the hypothalamus in
response to chronic high fat diet could be useful in appreciating
the neuropathology and the development of obesity. Understand-
ing the long and short term effects of PA-activated microglia
and OXA-mediated immunomodulation could lead to therapies
for maintaining neuronal networks involved in regulating healthy
metabolism.
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